Alnylam's (ALNY) Strong ALN-PCSsc Data at AHA Conference, FBR Capital Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St futures slip as oil surge puts markets on edge
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Alnylam Pharmaceuticals and The Medicines Company Announce that New ALN-PCSsc Results from Late-Breaking Presentation at American Heart Association Meeting Confirm Potential for Bi-Annual Hypercholest
November 11, 2015 10:45 AM ESTUp to 53 percent Maximal and 47 percent Least Squares Mean Reduction in LDL-C Achieved at 6 Months after Single, Low-Volume, Subcutaneous Injection
ALN-PCSsc Also Achieves Major Reductions in Other Atherogenic Lipids, Including Lowering of Lp(a) and Total Cholesterol of up to 77 percent and 55 percent, Respectively
Companies On Track to Initiate ORION-1 Phase 2 Trial by End-2015
Companies to Host Conference Call Today at 4:30 p.m.
CAMBRIDGE, Mass. & PARSIPPANY, N.J.--(BUSINESS WIRE)--... More
